A longitudinal study on the effects of azathioprine and high doses of prednisone on the immune system of kidney-transplant recipients

1982 ◽  
Vol 24 (1) ◽  
pp. 33-46 ◽  
Author(s):  
R.J.M.ten Berge ◽  
P.Th.A. Schellekens ◽  
S. Surachno ◽  
T.H. The ◽  
J.H.ten Veen ◽  
...  
2017 ◽  
Vol 42 (3) ◽  
pp. 187-189
Author(s):  
Yaira Hamama-Raz ◽  
Menachem Ben-Ezra ◽  
Yael Tirosh ◽  
Roni Baruch ◽  
Richard Nakache

2021 ◽  
Vol 10 (21) ◽  
pp. 5205
Author(s):  
Agnieszka Malinowska ◽  
Marta Muchlado ◽  
Zuzanna Ślizień ◽  
Bogdan Biedunkiewicz ◽  
Zbigniew Heleniak ◽  
...  

Introduction: Patients after SARS-CoV-2 infection frequently face “Post-COVID-19 Syndrome”, defined by symptoms that develop during or after COVID-19, continue for more than 12 weeks, and are not explained by an alternative diagnosis. We aimed to evaluate the presence of post-COVID-19 syndrome and its predictors in kidney transplant recipients (KTR) 6 months after the disease. Materials and Methods: A total of 67 KTR (38 m) with a mean age of 53.6 ± 14 years, 7.3 ± 6.4 years post-transplant were included in the cohort longitudinal study. Thirty-nine (58.2%) of them were hospitalized, but not one required invasive ventilation therapy. They were interviewed 6 months after being infected, with a series of standardized questionnaires: a self-reported symptoms questionnaire, the modified British Medical Research Council (mMRC) dyspnea scale, EQ-5D-5L questionnaire, and EQ-VAS scale. Results: Post-COVID-19 syndrome was diagnosed in 70.1% of KTR and 26.9% of them reported at least three persistent symptoms. The most common symptoms were fatigue (43.3%), hair loss (31.3%), memory impairment (11.9%), muscle aches, and headaches (11.9%). Dyspnea with an mMRC scale grade of at least 1 was reported by 34.3% patients vs. 14.9% before infection; 47.8% stated that they still feel worse than before the disease. Mean EQ-VAS scores were 64.83 vs. 73.34 before infection. The persistent symptoms are more frequent in older patients and those with greater comorbidity. Conclusions: Persistent symptoms of post-COVID-19 syndrome are present in the majority of KTR, which highlights the need for long-term follow-up as well as diagnostic and rehabilitation programs.


1996 ◽  
Vol 28 (1) ◽  
pp. 105-114 ◽  
Author(s):  
Vincent Pichette ◽  
Alain Bonnardeaux ◽  
Louis Prudhomme ◽  
Micheline Gagné ◽  
Jean Cardinal ◽  
...  

1981 ◽  
Vol 21 (1) ◽  
pp. 20-32 ◽  
Author(s):  
R.J.M. ten Berge ◽  
P.Th.A. Schellekens ◽  
S. Surachno ◽  
T.H. The ◽  
J.H. ten Veen ◽  
...  

Author(s):  
Maksims Čistjakovs ◽  
Alina Sultanova ◽  
Olga Jermakova ◽  
Svetlana Čapenko ◽  
Baiba Lesiņa-Korne ◽  
...  

Abstract Kidney transplant recipients have higher incidence of human papillomavirus (HPV)-related malignancies, but studies on the natural history of HPV infection are insufficient, especially regarding in male recipients. The aim of this study was to evaluate the course of high-risk HPV (HR-HPV) infection after kidney allograft transplantation in male recipients: to estimate frequency and activity of HR-HPV infection under immune system suppression. Twenty male renal recipients (age 20 - 68) were enrolled in this investigation and examined in dynamics. Peripheral EDTA-blood samples and urine samples were collected from each patient 2 weeks, 6 months and 12 months after transplantation. Polymerase chain reaction (PCR) with consensus primers was used for initial detection of high range HPV types, a commercial qPCR kit for detection of HR-HPV load in urine samples and ELISA for detection of serum IgG class antibodies to HR-HPV L1-capsid protein. Overall, combining molecular (HR-HPV genomic sequences detected by real-time PCR) and serological studies (IgG class antibodies to HR-HPV L1-capsids’ protein), high frequency of HRHPV infection among male kidney transplant recipients (9/20; 45%) was showed. However, the majority of HR-HPV positive recipients (7/9; 78%) showed signs of infection clearance. It means that, despite the applied immune suppressive therapy, the host’s immune system is capable of dealing with HR-HPV infection up to the 12th month after transplantation. However, the sample size should be increased to enable through statistical analysis before final conclusions are made.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1551-P
Author(s):  
THIZÁ M. LONDERO GAI ◽  
LUANA S. GIARETTA ◽  
ROBERTO C. MANFRO ◽  
LUIS H. CANANI ◽  
DANIEL LAVINSKY ◽  
...  

2017 ◽  
Vol 88 (4) ◽  
pp. 879-883
Author(s):  
Yaira Hamama-Raz ◽  
Menachem Ben-Ezra ◽  
Yael Tirosh ◽  
Roni Baruch ◽  
Richard Nakache

2018 ◽  
Vol 104 (2) ◽  
pp. 557-567 ◽  
Author(s):  
Thizá Massaia Londero ◽  
Luana Seminotti Giaretta ◽  
Luisa Penso Farenzena ◽  
Roberto Ceratti Manfro ◽  
Luis Henrique Canani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document